Search Results - "Zhong, Muyi"

The efficacy of human epidermal growth factor receptor 2 (HER2) blockade switching mode in refractory patients with HER2-positive metastatic breast cancer: a phase II, multicenter, single-arm study (SYSUCC-005) by Duan, Fangfang, Zhong, Muyi, Ma, Yuyu, Song, Chenge, Zhang, Lehong, Lin, Ying, Wu, Zhiyong, Zhang, Yuanqi, Huang, Jiajia, Xu, Fei, Shi, Yanxia, Wang, Shusen, Yuan, Zhongyu, Xia, Wen, Bi, Xiwen

“…Despite significant survival improvement in human epidermal growth factor receptor 2 (HER2) blockade for HER2-positive breast cancer, resistance to anti-HER2…”
Get full text

The Iron-Inflammation Axis in Early-Stage Triple-Negative Breast Cancer by Duan, Fangfang, Zhong, Muyi, Ye, Jinhui, Wang, Li, Jiang, Chang, Yuan, Zhongyu, Bi, Xiwen, Huang, Jiajia

“…The iron-related homeostasis and inflammatory biomarker have been identified as prognostic factors for cancers. We aimed to explore the prognostic value of a…”
Get full text

Current status and prospect of ZIF-based materials for breast cancer treatment by Zeng, Yana, Liao, Donghui, Kong, Xiangyang, Huang, Qianying, Zhong, Muyi, Liu, Jianqiang, Nezamzadeh-Ejhieh, Alireza, Pan, Ying, Song, Hailiang

“…Breast cancer, one of the three most life-threatening cancers in modern times, must be explored for treatments with low side effects and practical efficacy…”
Get full text

Current and promising applications of UiO-based MOFs in breast cancer therapy by Ma, Jiaxin, Chen, Zhimin, Diao, Yingyao, Ye, Min, Liu, Xingyan, Cui, Shien, Zhong, Muyi, Nezamzadeh-Ejhieh, Alireza, Liu, Jianqiang, Ouyang, Jie

“…Breast cancer is a malignant tumor disease with a high mortality rate. Therefore, improving breast cancer's efficacy is a research direction people have been…”
Get full text

The efficacy of human epidermal growth factor receptor 2 by Duan, Fangfang, Zhong, Muyi, Ma, Yuyu, Song, Chenge, Zhang, Lehong, Lin, Ying, Wu, Zhiyong, Zhang, Yuanqi, Huang, Jiajia, Xu, Fei, Shi, Yanxia, Wang, Shusen, Yuan, Zhongyu, Xia, Wen, Bi, Xiwen

“…Despite significant survival improvement in human epidermal growth factor receptor 2 (HER2) blockade for HER2-positive breast cancer, resistance to anti-HER2…”
Get full text